CRP and Insulin resistance: Previous studies have shown that metformin therapy was favorable for cardiovascular outcomes and the mechanisms might be partially related with its effects on improving insulin resistance, reducing serum level of C-reactive protein (CRP), enhancing eNOS expression and NO production, improving glycation and oxidative stress, and regulating glucose metabolism (Sena et al., 2011 ▶; Calvert et al., 2008 ▶; Liu et al., 2014 ▶).